ReviewNature reviews. Endocrinology2012
The pituitary tumour epigenome: aberrations and prospects for targeted therapy.
Review in Nature reviews. Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature.PloS one · 2013Pooled it
- CircVPS13C promotes pituitary adenoma growth by decreasing the stability of IFITM1 mRNA via interacting with RRBP1.Oncogene · 2022Article
- Architects of Pituitary Tumour Growth.Frontiers in endocrinology · 2022Review
- Potential biomarkers and lncRNA-mRNA regulatory networks in invasive growth hormone-secreting pituitary adenomas.Journal of endocrinological investigation · 2021Article
- Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"Cancers · 2020Review
- Molecular Network Basis of Invasive Pituitary Adenoma: A Review.Frontiers in endocrinology · 2019Review
- Genomic Alterations in Sporadic Pituitary Tumors.Current neurology and neuroscience reports · 2018Review
- Article
- Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.Journal of neuro-oncology · 2016Article
- EZH2 is highly expressed in pituitary adenomas and associated with proliferation.Scientific reports · 2015Article
- Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells.Pituitary · 2015Article
- Pathogenesis analysis of pituitary adenoma based on gene expression profiling.Oncology letters · 2014Article
- Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.Molecular and cellular endocrinology · 2014Review
- The role of genetic and epigenetic changes in pituitary tumorigenesis.Neurologia medico-chirurgica · 2014Review
- Advances in understanding pituitary tumors.F1000prime reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global and gene-specific changes in the epigenome are hallmarks of most tumour types, including those of pituitary origin. In contrast to genetic mutations, epigenetic changes (aberrant DNA methylation and histone modifications) are potentially reversible. Drugs that specifically target or inhibit DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) can be used to restore the expression of epigenetically silenced genes. These drugs can potentially increase the sensitivity of tumour cells to conventional treatment modalities, such as chemotherapy and radiotherapy. Drug-induced reversal of transcriptional silencing can also be used to restore dopamine-D(2)-receptor-negative, hormone-refractory tumours to their previous receptor-positive, hormone-responsive status. Synergy between HDAC and DNMT inhibitors makes these pharmacological agents more therapeutically effective when administered in combination than when used alone. Studies in pituitary tumour cell lines show that drug-induced re-expression of the epigenetically silenced dopamine D(2) receptor leads to an increase in apoptosis mediated by a receptor agonist. Collectively, the use of drugs to directly or indirectly reverse gene-specific epigenetic changes, in combination with conventional therapeutic interventions, has potential for the clinical management of multiple tumour types-including those of pituitary origin. Furthermore, these drugs can be used to identify epigenetically regulated genes that could be novel, tumour-specific therapeutic targets.
Indexed as
Identifiers
22525730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.